- Home
- CBUS
CBUS
Cibus Inc.
as 12-18-2024 9:33am EST
Cibus Inc is a biotechnology company. The company develops and commercializes a proprietary gene-editing technology, Rapid Trait Development System that integrates crop specific cell biology platforms with a series of gene editing technologies. The company's primary business is the development of plant traits that help address specific productivity or yield challenges in farming such as traits addressing plant agronomy, disease, insects, weeds, nutrient-use, or the climate.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 120.1M | IPO Year: | 2017 |
| Target Price: | $22.83 | AVG Volume (30 days): | 107.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -21.30 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.86 - $23.18 | Next Earning Date: | 11-07-2024 |
| Revenue: | $4,152,999 | Revenue Growth: | 449.34% |
| Revenue Growth (this year): | 99.17% | Revenue Growth (next year): | 67.09% |
Stock Insider Trading Activity of Cibus Inc. (CBUS)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Prante Gerhard | CBUS | Director | Dec 13 '24 | Sell | $3.87 | 1,150 | $4,450.50 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 12 '24 | Sell | $4.08 | 1,150 | $4,692.00 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 11 '24 | Sell | $4.35 | 1,150 | $5,002.50 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 10 '24 | Sell | $4.43 | 1,150 | $5,094.50 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 9 '24 | Sell | $4.15 | 1,150 | $4,772.50 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 6 '24 | Sell | $3.86 | 1,150 | $4,439.00 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 5 '24 | Sell | $4.00 | 1,150 | $4,600.00 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 4 '24 | Sell | $4.39 | 1,150 | $5,048.50 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 3 '24 | Sell | $4.69 | 1,150 | $5,393.50 | 56,007 | |
| Prante Gerhard | CBUS | Director | Dec 2 '24 | Sell | $4.46 | 2,300 | $10,258.00 | 56,007 |
Latest Cibus Inc. News
CBUS Breaking Stock News: Dive into CBUS Ticker-Specific Updates for Smart Investing
TipRanks
a day ago
Cibus, Albaugh, RTDC affirm collaboration for weed management solution
GlobeNewswire
2 days ago
Cibus, Albaugh LLC and RTDC Company Limited Affirm Collaboration to Enable Commercialization of Cibus’ First Gene Edited Weed Management Solution for U.S. Rice Growers
GlobeNewswire
a month ago
Cibus and Biographica Announce Collaboration Using Artificial Intelligence (AI) to Advance Disease Resistance in Canola and Oilseed Rape
GlobeNewswire
a month ago
Cibus to Participate in the 13th Annual Roth Technology Conference
GlobeNewswire
a month ago
Cibus Achieves Additional Milestone for Next Generation Gene Edits for Sclerotinia Resistance in Canola
GuruFocus.com
a month ago
Cibus Inc (CBUS) Q3 2024 Earnings Call Highlights: Navigating Challenges and Seizing ...
Simply Wall St.
a month ago
Cibus Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
GlobeNewswire
a month ago
Cibus Reports Third Quarter Financial Results and Provides Year-to-Date Business Update for 2024
Compare CBUS vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CBUS Cibus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.